NO20025667D0 - Midler og metoder for å öke nivåene av chaperoner i hjernen - Google Patents

Midler og metoder for å öke nivåene av chaperoner i hjernen

Info

Publication number
NO20025667D0
NO20025667D0 NO20025667A NO20025667A NO20025667D0 NO 20025667 D0 NO20025667 D0 NO 20025667D0 NO 20025667 A NO20025667 A NO 20025667A NO 20025667 A NO20025667 A NO 20025667A NO 20025667 D0 NO20025667 D0 NO 20025667D0
Authority
NO
Norway
Prior art keywords
methoxychlor
pharmaceutical compositions
pharmaceutically acceptable
acceptable carrier
compound
Prior art date
Application number
NO20025667A
Other languages
English (en)
Other versions
NO20025667L (no
NO330175B1 (no
Inventor
Jordan Holtzman
Original Assignee
Jordan Holtzman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jordan Holtzman filed Critical Jordan Holtzman
Publication of NO20025667D0 publication Critical patent/NO20025667D0/no
Publication of NO20025667L publication Critical patent/NO20025667L/no
Publication of NO330175B1 publication Critical patent/NO330175B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/085Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Glass Compositions (AREA)
NO20025667A 2000-05-24 2002-11-25 Anvendelse av 1,1,1-triklor-2,2-bis-(4-metoksyfenyl)etan til fremstilling av et medikament for behandling av Alzheimers sykdom eller for a lindre et symptom pa Alzheimers sykdom NO330175B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20685400P 2000-05-24 2000-05-24
PCT/US2001/016914 WO2001089500A2 (en) 2000-05-24 2001-05-23 Agents and methods for increasing brain chaperonin levels

Publications (3)

Publication Number Publication Date
NO20025667D0 true NO20025667D0 (no) 2002-11-25
NO20025667L NO20025667L (no) 2003-01-22
NO330175B1 NO330175B1 (no) 2011-02-28

Family

ID=22768251

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025667A NO330175B1 (no) 2000-05-24 2002-11-25 Anvendelse av 1,1,1-triklor-2,2-bis-(4-metoksyfenyl)etan til fremstilling av et medikament for behandling av Alzheimers sykdom eller for a lindre et symptom pa Alzheimers sykdom

Country Status (13)

Country Link
US (2) US20030216480A1 (no)
EP (1) EP1289512B1 (no)
JP (1) JP4965048B2 (no)
AT (1) ATE290373T1 (no)
AU (2) AU2001263421B2 (no)
CA (1) CA2410395A1 (no)
DE (1) DE60109286T2 (no)
HK (1) HK1053987A1 (no)
IL (2) IL153058A0 (no)
MX (1) MXPA02011675A (no)
NO (1) NO330175B1 (no)
NZ (1) NZ522951A (no)
WO (1) WO2001089500A2 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750048B2 (en) * 2006-11-15 2010-07-06 Janssen Pharmaceutica Nv GPR40 agonists
KR101275264B1 (ko) * 2011-08-24 2013-06-17 포항공과대학교 산학협력단 샤프로닌 단백질의 조절 물질 탐색 방법
WO2014012108A1 (en) * 2012-07-13 2014-01-16 Holtzman Jordan L Cellular and animal models for screening therapeutic agents for the treatment of alzheimer's disease
CN111505001A (zh) * 2020-06-12 2020-08-07 山东省医学科学院基础医学研究所 一种蛋白单磷酸尿苷酸化修饰的检测方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2535000A (en) * 1949-04-29 1950-12-19 Moorman Mfg Company Insecticidal composition comprising ddt and methoxychlor
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
CA1187409A (en) * 1983-02-09 1985-05-21 George S. Puritch Insecticide mixtures containing fatty acids
US4636524A (en) * 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
EP1649850A1 (en) * 1993-11-19 2006-04-26 Alkermes Controlled Therapeutics Inc. II Preparation of biodegradable microparticles containing a biologically active agent
US5985242A (en) * 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
WO1998043647A1 (en) * 1997-03-28 1998-10-08 Massachusetts Institute Of Technology, Inc. Regulation of amyloid precursor protein (app) expression by estrogenic compounds
IL136306A (en) * 1997-12-10 2005-09-25 Nps Pharma Inc Bis (fluorophenyl) alkylamides and related compounds, pharmaceutical compositions comprising them and their use in treating neurological disease or disorder
WO2000026251A2 (en) * 1998-10-30 2000-05-11 Holtzman Jordan L A COMPLEX OF A CHAPERONE WITH ss-AMYLOID AND METHODS EMPLOYING THIS COMPLEX
MXPA01007486A (es) * 1999-01-25 2003-06-24 Optime Therapeutics Inc Formulaciones de liposomas.

Also Published As

Publication number Publication date
NO20025667L (no) 2003-01-22
US20030216480A1 (en) 2003-11-20
DE60109286D1 (de) 2005-04-14
AU6342101A (en) 2001-12-03
MXPA02011675A (es) 2004-07-30
WO2001089500A3 (en) 2002-04-25
IL153058A0 (en) 2003-06-24
JP4965048B2 (ja) 2012-07-04
NZ522951A (en) 2004-11-26
AU2001263421B2 (en) 2006-05-18
WO2001089500A2 (en) 2001-11-29
EP1289512A2 (en) 2003-03-12
DE60109286T2 (de) 2005-07-28
ATE290373T1 (de) 2005-03-15
JP2003535829A (ja) 2003-12-02
EP1289512B1 (en) 2005-03-09
IL153058A (en) 2010-05-31
HK1053987A1 (zh) 2003-11-14
US20100152303A1 (en) 2010-06-17
NO330175B1 (no) 2011-02-28
CA2410395A1 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
EA200400881A1 (ru) Азаарилпиперазины
DK1123094T3 (da) Terapeutiske præparater (II)
DE69331409D1 (de) Oral 1alpha-hydroxyprevitamin d
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
HUP0300027A2 (en) Nucleoside analogs with carboxamidine modified monocyclic base and process for their use
NO20053077L (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
WO2001054681A8 (en) Composition for treatment of stress
HUP9800467A2 (hu) Hialuronsav alkalmazása szövetközi cisztitisz kezelésére alkalmas gyógyászati készítmények előállítására
DE69943107D1 (de) Behandlung von autoimmunerkrankungen
ATE283047T1 (de) Verwendung von ibudilast zur herstellung eines arzneimittels zur behandlung multiple sklerose
DE3879873D1 (de) Physiologisch aktive substanzen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
EA200400548A1 (ru) Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)
KR970025615A (ko) 암 전이 억제제
DE69428325T2 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen Derivaten zur Herstellung eines Medikaments zur Hemmung der Angiogenese und angiogene Krankheiten
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
NO20025667D0 (no) Midler og metoder for å öke nivåene av chaperoner i hjernen
DK0629400T3 (da) Idebenon-holdige præparater til behandling af Alzheimer's syge
EP1323422B8 (en) Pharmaceutical composition comprising midazolam for buccal administration
BR9809673A (pt) Derivados de triptolida úteis no tratamento de doenças autoimunes
HUP0204391A2 (en) The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders
GB9205670D0 (en) New derivatives of physostigmine,their use and pharmaceutical formulations containing them
NO20044698L (no) Statinterapi for a oke kognitiv opprettholdelse
ATE293445T1 (de) Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees